Thyroid hormone, immunoglobin and complements for predicting hepatocellular carcinoma development in patients with hepatitis B virus-related liver cirrhosis

Table 4 Risk factors for hepatocellular carcinoma in patients with liver cirrhosis (training set)

Baseline variables	Univariate			Multivariate
	OR	95%CI	P value	OR	95%CI	P value
Age (years)	1.081	1.029-1.135	< 0.01	1.068	1.014-1.125	0.01
Male	0.664	0.224-1.969	0.46
Decompensated cirrhosis	6.815	1.888-24.597	< 0.01	4.703	1.180-18.745	0.03
Diabetes	2.962	1.104-7.944	0.03
Alanine transaminase (U/L)	0.991	0.978-1.004	0.18
Gamma-glutamyl transpeptidase (U/L)	1.005	0.999-1.011	0.08	1.007	1.001-1.014	0.03
Total bilirubin (µmol/L)	1.007	0.982-1.033	0.57
International normalized ratio	0.746	0.081-6.888	0.80
Platelet (E+09/L)	0.990	0.979-1.000	0.05
Total triiodothyronine (nmol/L)	0.395	0.120-1.298	0.13
Total tetraiodothyronine (nmol/L)	0.997	0.980-1.014	0.73
Free triiodothyronine (pmol/L)	0.738	0.423-1.290	0.29
Free tetraiodothyronine (pmol/L)	0.949	0.749-1.203	0.67
Thyroid-stimulating hormone (μIU/mL)	1.101	0.683-1.776	0.69

OR: Odds ratio.